The label words, in plain language
- Gastroesophageal reflux disease (GERD): stomach contents coming back up into the food pipe. The Wegovy® Medication Guide calls it heartburn [1].
- Dyspepsia: indigestion or an upset stomach, usually discomfort in the upper abdomen during or after eating.
- Gastritis: inflammation of the stomach lining. In the Wegovy® table this term also covers chronic, erosive and reflux gastritis [1].
- Eructation: belching. It is covered in more detail in a separate article on burping.
Weight-management labels: rates against placebo
Each row is a placebo-controlled pool from section 6.1. Ranges cover dose groups, and the labels caution against comparing rates across different drugs’ trials.
- The Wegovy® adult pool also lists gastritis in 4% against 1% and belching in 7% against less than 1% [1].
| Label and trial pool | GERD: placebo vs medicine | Dyspepsia: placebo vs medicine |
|---|---|---|
| Wegovy® 2.4 mg: three adult trials, up to 68 weeks [1] | 3% vs 5% | 3% vs 9% |
| Wegovy®: adolescent trial [1] | 2% vs 4% | not in the table |
| Zepbound®: two trials, up to 72 weeks [2] | 2% vs 4–5% | 4% vs 9–10% |
| Foundayo™: two trials, up to 72 weeks [3] | 2% vs 6–7% | 4% vs 12–16% |
| Saxenda®: adult weight management trials [4] | 1.7% vs 4.7% | 2.7% vs 9.6% |
Type 2 diabetes labels: lower rates, lower doses
The diabetes labels mostly report these terms in the text of section 6.1, below their 5% table threshold. Mounjaro®, placebo-controlled trials in type 2 diabetes: dyspepsia is in the table at 5% to 8% across doses versus 3%, and GERD in the text at 1.7% to 2.5% versus 0.4%. Ozempic®: GERD 1.9% on 0.5 mg and 1.5% on 1 mg versus 0%; dyspepsia 3.5% and 2.7% versus 1.9%. Rybelsus®: GERD 2% on both doses versus 0.3% [5][6][7].
These pools differ from the weight-management trials in doses, length and the people enrolled, so the numbers are not directly comparable.
European, Canadian and pooled-trial data
In the European leaflets, reflux or heartburn and indigestion are listed as common, meaning up to 1 in 10 people, for Ozempic®, Wegovy®, Rybelsus® and Mounjaro® [8][9]. The European Ozempic® summary adds a detail missing from the US label: in SUSTAIN 9, where semaglutide 1 mg was added to an SGLT2 inhibitor, reflux occurred in 4% of people against none on placebo, and it did not become less frequent over time [8].
The Canadian Zepbound® monograph, revised in June 2026, gives GERD by dose as 4.3%, 3.9% and 4.6% on 5, 10 and 15 mg against 2.1% on placebo, in line with the US figures [10].
A systematic review and meta-analysis published in Gastroenterology in 2025 pooled 55 randomised placebo-controlled trials with 106,395 participants, in diabetes, obesity and fatty liver disease. GLP-1 medicines probably increased the risk of GERD (risk ratio 2.19), which the authors translated into about 4 more cases per 1,000 people. The increase looked larger in weight-loss and high-dose trials, but those subgroup differences were not statistically significant [11].
Why it might happen
- What the labels state: the Wegovy® label says its stomach-related reactions, a list that includes dyspepsia, GERD and gastritis, were most frequently reported during dosage escalation. The tirzepatide and orforglipron labels say the same of nausea, vomiting and diarrhea, which decreased over time [1][2][3].
- What the labels do not connect: all of these labels describe delayed gastric emptying as one of the medicine’s actions, and use it to explain possible effects on oral medicines and the anesthesia warning. They do not say it is why reflux happens, and we did not find that link tested in the sources used here [1][2].
- General mechanism: MedlinePlus explains that reflux happens when the ring of muscle at the bottom of the food pipe does not close fully, and lists lying down soon after eating, alcohol, smoking, obesity, pregnancy and a hiatal hernia among the risk factors [12].
Other possible causes
MedlinePlus lists several medicines that can cause or worsen heartburn, including some blood pressure and heart medicines (beta-blockers and calcium channel blockers), asthma medicines, tricyclic antidepressants, sedatives and progestin. It asks you not to change or stop a medicine without talking to your provider first [12].
Heartburn can also be confused with dyspepsia, and MedlinePlus warns that some people who think they have heartburn are having a heart attack [13]. Trouble swallowing and hoarseness deserve attention for another reason too: the GLP-1 labels list them among the symptoms to report under the thyroid tumor warning [1][6].
What general guidance says helps
- Triggers: foods and drinks often linked to reflux include alcohol, caffeine, fizzy drinks, chocolate, citrus and tomatoes, mint, and spicy or fatty foods. NIDDK suggests talking with your doctor about which ones seem to affect you rather than cutting everything at once [13][14].
- Meal habits: eat smaller meals, avoid bending over or exercising straight after eating, and leave some hours between your last meal and lying down [12][13][14].
- At night and during the day: raising the head of the bed helps if symptoms are worse at night; loose clothing around the waist and stopping smoking also appear in the MedlinePlus list [12][13].
- Over-the-counter options: MedlinePlus describes antacids, H2 blockers and proton pump inhibitors, notes that antacids can cause diarrhea or constipation, and says your pharmacist or provider can explain how to take them [12][13]. The GLP-1 labels ask you to tell your provider about everything you take, since slower stomach emptying can affect tablets [1][6].
- If self-care is not enough: MedlinePlus asks you to contact your provider if heartburn is frequent or has not gone away after a few weeks [13].
Before surgery or sedation
Each label warns that there have been rare reports of food or liquid getting into the lungs (pulmonary aspiration) during general anesthesia or deep sedation in people taking GLP-1 medicines, who had food left in the stomach despite fasting as instructed. The labels ask you to tell every healthcare provider that you take the medicine before any planned surgery or procedure [1][2][6].
If you have reflux symptoms, mention them at the same time. How to prepare for the procedure is decided by the team performing it.
How a log helps
Reflux tends to follow a pattern that is easier to see on paper: how many days after the dose it appears, whether it comes after large or late meals or when lying down, and whether it eases as the weeks pass at the same dose. Writing down any over-the-counter remedy you used also helps, since the labels ask you to tell your provider about everything you take.
Ozempic®, Wegovy®, Rybelsus® and Saxenda® are registered trademarks of Novo Nordisk A/S. Mounjaro® and Zepbound® are registered trademarks of Eli Lilly and Company, and Foundayo™ is a trademark of Eli Lilly and Company. PepLabo is not affiliated with or endorsed by Novo Nordisk or Eli Lilly.
When to get help
| Sign | Who to contact | How fast | Source |
|---|---|---|---|
| Vomiting blood or material that looks like coffee grounds, or black or maroon stools | Urgent medical care | Emergency | MedlinePlus, heartburn [13] |
| A burning feeling with squeezing, crushing or pressure in the chest | Call 911 or your local emergency number: it may be the heart | Emergency | MedlinePlus, heartburn [13] |
| Intense belly pain that persists, with or without vomiting, and may reach the back | Stop the medicine and call your provider right away | Emergency | Labels, pancreatitis warning [1][2] |
| Trouble or pain swallowing, food or pills sticking behind the breastbone, frequent vomiting or choking | Your provider | Today | MedlinePlus, GERD [12] |
| Hoarseness, trouble swallowing or a lump in the neck | Tell your prescriber; the labels list these in the thyroid tumor warning | Today | Labels, boxed warning [1][6] |
| Heartburn that is frequent, lasts beyond a few weeks of self-care, or comes with weight loss you did not intend | Bring your notes to your provider | At your next appointment | MedlinePlus, heartburn [13] |
